%0 Journal Article
%T Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report
%A Bixiu He
%A Chengping Hu
%A Dongbo Zhou
%A Min Li
%A Yan Zhang
%J Archive of "OncoTargets and therapy".
%D 2019
%R 10.2147/OTT.S188612
%X T790M mutation is well known as the most common mechanism for resistance to the first- and second-generation tyrosine kinase inhibitors (TKIs) for EGFR mutation in non-small-cell lung cancer. Several third-generation EGFR TKIs, such as osimertinib, have been explored and approved for conquering this resistance; however, acquired resistance to osimertinib is evident and the resistance mechanisms remain complex and incompletely explored
%K NSCLC
%K EGFR mutation
%K tyrosine kinase inhibitor
%K next-generation sequencing
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302808/